LRRK2 and Parkinson disease: Pharmacological inhibition of LRRK2 using small molecules targeting its kinase activity are entering the clinical evaluation for the treatment of Parkinson's disease [42], and promising safety data have been reported with the first‐in‐class compound DNL201 [54].